Genetic testing can make a major contribution to the fight against Coronavirus / COVID-19. Find out how a simple saliva test can help hospitals manage during the coronavirus outbreak.
The PGX – Psychiatry® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect, or cause adverse effects. It is an easily administered cheek swab test (buccal swab) that analyzes key genes, selected based on hundreds of studies showing that variations in these genes can inform treatment decisions.
PGX – Psychiatry is used to guide treatment for a range of psychiatric conditions, including:
- Obsessive-Compulsive Disorder (OCD)
- Attention Deficit hyperactivity Disorder (ADHD)
- Bipolar Disorder
- Post Traumatic Stress Disorder (PTSD)
- chronic pain
- substance abuse
PGX – Psychiatry has been shown in peer reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy to read patient report and a complimentary psychopharmacogenomic consultation. Genomind is always searching for ways to improve upon the traditional trial and error process of drug prescribing in psychiatry. As such, we have conducted and continue to conduct a number of studies in order to present objective data on how the PGX – Psychiatry® can help patients feel better, faster. Clinical evidence has shown PGX – Psychiatry has resulted in better treatment response and patient compliance, as well as decreased healthcare costs.